RecruitingNCT06299553

Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

INCB88888-040 Multicenter Prospective Real-world Observational Cohort Study to Evaluate the Effectiveness of Tafasitamab in Combination With Lenalidomide Followed by Tafasitamab Monotherapy in Relapsed or Refractory Diffuse Large B-cell Lymphoma Non-transplant Eligible Patients in Italy (PRO-MIND)

Sponsor

Incyte Biosciences Italy S.r.l

Enrollment

200 participants

Start Date

Dec 4, 2023

Study Type

OBSERVATIONAL

Conditions

DLBCL - Diffuse Large B Cell Lymphoma

Summary

The PRO-MIND study is an Italian, multicenter, prospective observational cohort study to evaluate the effectiveness and the safety of tafasitamab in combination with lenalidomide followed by tafasitamab monotherapy in patient with DLBCL.

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Patients are aged 18 years or older.
Patients with DLBCL R/R disease non-transplant eligible.
Patients who will initiate the treatment with commercially available tafasitamab and lenalidomide after the ICF signature. The decision to prescribe tafasitamab must have been made prior and regardless of the enrollment of the patient in the study.
Patients are able of giving the signed informed consent.

Exclusion Criteria3

Concomitant participation in an interventional clinical study
Any patient in the physician's opinion from whom initial diagnosis or follow-up data is unlikely to be obtained reliably data for the purposes of this observational study.
Patients who started tafasitamab treatment before signing the ICF.